Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination vs Concurrent Chemotherapy in High Risk Nasopharyngeal Carcinoma
NCT02621970Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2016
- Primary completion
- Jan 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
docetaxelcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02621970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621970.